← Back
Clover Health Investments
CLOV · listed on Nasdaq · worth $2.32 billion
$4.58
−4.38% on Oct 29
No insider bought Clover Health Investments stock in the last year. They sold it 34 times, $5.13 million in all.
Red dot = an insider sold◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
412.7M shares
95% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, seven insiders sold Clover Health Investments stock and none bought. 21 of the 34 sales are marked on the filing as planned in advance; most by company executives. The biggest seller was Andrew Toy, Chief Executive Officer.
Planned sales
Form 144 notices filed for Clover Health Investments in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
Executive Karen Soares filed to sell 19,275 shares on 20 Oct; sold 19,275 by 20 Oct10b5-1 plan adopted 13 Mar 2026 · Notice on SEC.gov
CEO Jamie L. Reynoso filed to sell 4,066 shares on 19 Oct; sold 4,066 by 19 Oct10b5-1 plan adopted 12 Mar 2026 · Notice on SEC.gov
CEO Andrew Toy filed to sell 60,765 shares on 15 Oct; sold 62,176 by 15 OctNotice on SEC.gov
All reports
Every insider trade and SEC report we hold for Clover Health Investments.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Oct 20SoldKaren SoaresOct 20 · Chief Legal Officer · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.19,275 @ $4.66$89.8K
Oct 20SoldJamie L. ReynosoOct 20 · Traded Oct 19 · CEO, Medicare Advantage · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.4,066 @ $4.41$17.9K
Oct 19SoldAndrew ToyOct 19 · Traded Oct 15 · Chief Executive Officer · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.62,176 @ $4.68$291K
Oct 19SoldJamie L. ReynosoOct 19 · Traded Oct 15 · CEO, Medicare Advantage · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.18,273 @ $4.68$85.5K
Oct 7SoldJamie L. ReynosoOct 7 · CEO, Medicare Advantage · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.2,006 @ $4.63$9.3K
42 more with Pro →Analysts, earnings and news
Analysts' price target
$4.15 average
3 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
3 of 4 quarters above
Q1 '26$0.07 a share+$0.00
Q4 '25−$0.05 a share+$0.00
Q3 '25$0.00 a share−$0.02
Q2 '25$0.03 a share+$0.00